These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 15695378

  • 1. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ, Liu ZJ, Shimoi K, Zhu BT.
    Cancer Res; 2005 Jan 15; 65(2):387-93. PubMed ID: 15695378
    [Abstract] [Full Text] [Related]

  • 2. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
    Liu ZJ, Lee WJ, Zhu BT.
    Cancer Res; 2005 Jul 01; 65(13):5802-11. PubMed ID: 15994956
    [Abstract] [Full Text] [Related]

  • 3. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ, Zhu BT.
    J Steroid Biochem Mol Biol; 2004 Mar 01; 88(3):265-75. PubMed ID: 15120420
    [Abstract] [Full Text] [Related]

  • 4. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H, Miyoshi S.
    Cancer Sci; 2011 Nov 01; 102(11):2038-42. PubMed ID: 21801281
    [Abstract] [Full Text] [Related]

  • 5. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
    Liu Y, Lu WL, Guo J, Du J, Li T, Wu JW, Wang GL, Wang JC, Zhang X, Zhang Q.
    J Control Release; 2008 Jul 02; 129(1):18-25. PubMed ID: 18466993
    [Abstract] [Full Text] [Related]

  • 6. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice.
    Lin YJ, Zhen YS.
    Anticancer Drugs; 2009 Jan 02; 20(1):65-72. PubMed ID: 19343002
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
    Mueck AO, Seeger H, Huober J.
    Life Sci; 2004 Jul 23; 75(10):1205-10. PubMed ID: 15219808
    [Abstract] [Full Text] [Related]

  • 8. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S, Wientjes MG, Walsh C, Au JL.
    Cancer Res; 2001 Aug 15; 61(16):6145-50. PubMed ID: 11507065
    [Abstract] [Full Text] [Related]

  • 9. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May 15; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

  • 10. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
    Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S.
    Cancer Res; 2006 Apr 15; 66(8):4309-18. PubMed ID: 16618756
    [Abstract] [Full Text] [Related]

  • 11. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
    Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J, Matsuo K, Noguchi S, Kiniwa M.
    Breast Cancer Res Treat; 2011 Jul 15; 128(2):381-90. PubMed ID: 20809360
    [Abstract] [Full Text] [Related]

  • 12. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F, Duivenvoorden WC, Singh G.
    Anticancer Drugs; 2009 Feb 15; 20(2):115-22. PubMed ID: 19209028
    [Abstract] [Full Text] [Related]

  • 13. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
    Dai D, Holmes AM, Nguyen T, Davies S, Theele DP, Verschraegen C, Leslie KK.
    Cancer Res; 2005 Oct 15; 65(20):9517-24. PubMed ID: 16230417
    [Abstract] [Full Text] [Related]

  • 14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 15. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R, Tanabe K, Emi M, Uchida Y, Osaki A, Toge T.
    Int J Oncol; 2005 Apr 15; 26(4):1025-31. PubMed ID: 15753998
    [Abstract] [Full Text] [Related]

  • 16. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer.
    Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG.
    Clin Cancer Res; 2005 Mar 01; 11(5):1722-32. PubMed ID: 15755993
    [Abstract] [Full Text] [Related]

  • 17. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 18. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
    Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R.
    Cancer Res; 2000 Apr 01; 60(7):2040-8. PubMed ID: 10766196
    [Abstract] [Full Text] [Related]

  • 19. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
    Shi P, Wang MM, Jiang LY, Liu HT, Sun JZ.
    Chin Med J (Engl); 2008 Oct 20; 121(20):1975-9. PubMed ID: 19080259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.